|
|
Blood, 1 February 2006, Vol. 107, No. 3, pp. 904-906.
Prepublished online as a Blood First Edition Paper on October 6, 2005; DOI 10.1182/blood-2005-08-3449.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Brief report
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
Ola Landgren,
Gloria Gridley,
Ingemar Turesson,
Neil E. Caporaso,
Lynn R. Goldin,
Dalsu Baris,
Thomas R. Fears,
Robert N. Hoover, and
Martha S. Linet
From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD; and Section of Hematology, Department of Medicine, Malmö University Hospital, University of Lund, Malmö, Sweden.
The age-adjusted incidence of multiple myeloma (MM) is 2-fold higher in African Americans than in whites. A few small studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS) in African Americans versus whites. Etiologic factors for MGUS and determinants for transformation of MGUS to MM are unknown. We quantified the prevalence of MGUS and subsequent risk of MM among 4 million African American and white male veterans admitted to Veterans Affairs (VA) hospitals. The age-adjusted prevalence ratio of MGUS in African Americans compared with whites was 3.0 (2.7-3.3 95% confidence interval). Among 2046 MGUS cases, the estimated cumulative risk of MM during the first 10 years of follow-up was similar (P = .37) for African Americans (17%) and whites (15%). In the largest study to date, we suggest that the excess risk of MM in African Americans results from an increase in risk of MGUS rather than an increased risk of progression from MGUS to MM.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. K. Kumar, J. R. Mikhael, F. K. Buadi, D. Dingli, A. Dispenzieri, R. Fonseca, M. A. Gertz, P. R. Greipp, S. R. Hayman, R. A. Kyle, et al.
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Mayo Clin. Proc.,
December 1, 2009;
84(12):
1095 - 1110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y. Kristinsson, L. R. Goldin, M. Bjorkholm, J. Koshiol, I. Turesson, and O. Landgren
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
Haematologica,
November 1, 2009;
94(11):
1581 - 1589.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance
Clin. Cancer Res.,
September 15, 2009;
15(18):
5606 - 5608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Vachon, R. A. Kyle, T. M. Therneau, B. J. Foreman, D. R. Larson, C. L. Colby, T. K. Phelps, A. Dispenzieri, S. K. Kumar, J. A. Katzmann, et al.
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Blood,
July 23, 2009;
114(4):
785 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, S. Y. Kristinsson, L. R. Goldin, N. E. Caporaso, C. Blimark, U.-H. Mellqvist, A. Wahlin, M. Bjorkholm, and I. Turesson
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden
Blood,
July 23, 2009;
114(4):
791 - 795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, R. A. Kyle, R. M. Pfeiffer, J. A. Katzmann, N. E. Caporaso, R. B. Hayes, A. Dispenzieri, S. Kumar, R. J. Clark, D. Baris, et al.
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Blood,
May 28, 2009;
113(22):
5412 - 5417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Weiss, J. Abadie, P. Verma, R. S. Howard, and W. M. Kuehl
A monoclonal gammopathy precedes multiple myeloma in most patients
Blood,
May 28, 2009;
113(22):
5418 - 5422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Tancred, A. R. Belch, T. Reiman, L. M. Pilarski, and J. Kirshner
Altered Expression of Fibronectin and Collagens I and IV in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance
J. Histochem. Cytochem.,
March 1, 2009;
57(3):
239 - 247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Iwanaga, M. Tagawa, K. Tsukasaki, T. Matsuo, K.-i. Yokota, Y. Miyazaki, T. Fukushima, T. Hata, Y. Imaizumi, D. Imanishi, et al.
Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors
Blood,
February 19, 2009;
113(8):
1639 - 1650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. T. Lynch, K. Ferrara, B. Barlogie, E. A. Coleman, J. F. Lynch, D. Weisenburger, W. Sanger, P. Watson, H. Nipper, V. Witt, et al.
Familial Myeloma
N. Engl. J. Med.,
July 10, 2008;
359(2):
152 - 157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, L. R. Goldin, N. E. Caporaso, R. A. Kyle, and S. V. Rajkumar
Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance-reply-I
Mayo Clin. Proc.,
May 1, 2008;
83(5):
602 - 603.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Brown, G. Gridley, D. Check, and O. Landgren
Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders
Blood,
April 1, 2008;
111(7):
3388 - 3394.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, J. A. Katzmann, A. W. Hsing, R. M. Pfeiffer, R. A. Kyle, E. D. Yeboah, R. B. Biritwum, Y. Tettey, A. A. Adjei, D. R. Larson, et al.
Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana
Mayo Clin. Proc.,
December 1, 2007;
82(12):
1468 - 1473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Iwanaga, M. Tagawa, K. Tsukasaki, S. Kamihira, and M. Tomonaga
Prevalence of Monoclonal Gammopathy of Undetermined Significance: Study of 52,802 Persons in Nagasaki City, Japan
Mayo Clin. Proc.,
December 1, 2007;
82(12):
1474 - 1479.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, I. Turesson, G. Gridley, and N. E. Caporaso
Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease
Arch Intern Med,
June 11, 2007;
167(11):
1189 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Cook and D. H C Macdonald
Management of paraproteinaemia
Postgrad. Med. J.,
April 1, 2007;
83(978):
217 - 223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, J. S. Rapkin, N. E. Caporaso, L. Mellemkjaer, G. Gridley, L. R. Goldin, and E. A. Engels
Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia
Blood,
March 1, 2007;
109(5):
2198 - 2201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Blade
Monoclonal Gammopathy of Undetermined Significance
N. Engl. J. Med.,
December 28, 2006;
355(26):
2765 - 2770.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Landgren, G. Gridley, T. R. Fears, and N. Caporaso
Immune thrombocytopenic purpura does not exhibit a disparity in prevalence between African American and white veterans
Blood,
August 1, 2006;
108(3):
1111 - 1112.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. Cohen, R. A. Kyle, S. V. Rajkumar, and L. J. Melton III
Prevalence of monoclonal gammopathy of undetermined significance.
N. Engl. J. Med.,
June 29, 2006;
354(26):
2832 - 2832.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar, A. Dispenzieri, and R. A. Kyle
Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment
Mayo Clin. Proc.,
May 1, 2006;
81(5):
693 - 703.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
